Invion Stock

Invion Financing Cash Flow

The Net Financing Cash Flow of Invion (IVX.AX) as of Sep 12, 2026 is 3.04 M AUD.

Financing Cash Flow

3.04 MAUD

Last updated:

Net Financing Cash Flow of Invion is 2026 3.04 M AUD. Net Financing Cash Flow of Invion was 2025 0.00 AUD. It decreases by % higher compared to the previous year.

The Invion Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
678,900.00 AUD
Jan 1, 2018
1.27 M AUD
Jan 1, 2019
0.00 AUD
Jan 1, 2021
0.00 AUD
Jan 1, 2022
15.80 M AUD
Jan 1, 2023
0.00 AUD
Jan 1, 2024
0.00 AUD
Jan 1, 2025
3.04 M AUD
The Invion Financing Cash Flow history
YEARFinancing Cash FlowYoY
3.04 MAUD
0.00AUD
0.00AUD-100.00%
15.80 MAUD
0.00AUD
0.00AUD-100.00%
1.27 MAUD+86.80%
678,900.00AUD-64.16%
1.89 MAUD-78.13%
8.66 MAUD+56.58%
5.53 MAUD
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Net Financing Cash Flow of Invion is 3.04 M AUD in 2026.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Invion since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Invion historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Invion

All Key Metrics — Invion